Native T1 is predictive of cardiovascular death/heart failure events and all-cause mortality irrespective of the patient's volume status.
T1
T1-mapping
cardiovascular magnetic resonance (CMR)
heart failure
plasma volume
prognosis
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
11
2022
accepted:
19
01
2023
entrez:
3
3
2023
pubmed:
4
3
2023
medline:
4
3
2023
Statut:
epublish
Résumé
Native T1 has become a pivotal parameter of tissue composition that is assessed by cardiac magnetic resonance (CMR). It characterizes diseased myocardium and can be used for prognosis estimation. Recent publications have shown that native T1 is influenced by short-term fluctuations of volume status due to hydration or hemodialysis. Patients from a prospective BioCVI all-comers clinical CMR registry were included, and native T1 and plasma volume status (PVS) were determined according to Hakim's formula as surrogate markers of patient volume status. The primary endpoint was defined as combined endpoint of cardiovascular death or hospitalization for heart failure events, the secondary endpoint was defined as all-cause mortality. A total of 2,047 patients were included since April 2017 [median (IQR); age 63 (52-72) years, 33% female]. There was a significant although weak influence of PVS on native T1 ( Despite a weak effect of PVS on native T1, its predictive power was not affected in a large, all-comers cohort.
Sections du résumé
Background
UNASSIGNED
Native T1 has become a pivotal parameter of tissue composition that is assessed by cardiac magnetic resonance (CMR). It characterizes diseased myocardium and can be used for prognosis estimation. Recent publications have shown that native T1 is influenced by short-term fluctuations of volume status due to hydration or hemodialysis.
Methods
UNASSIGNED
Patients from a prospective BioCVI all-comers clinical CMR registry were included, and native T1 and plasma volume status (PVS) were determined according to Hakim's formula as surrogate markers of patient volume status. The primary endpoint was defined as combined endpoint of cardiovascular death or hospitalization for heart failure events, the secondary endpoint was defined as all-cause mortality.
Results
UNASSIGNED
A total of 2,047 patients were included since April 2017 [median (IQR); age 63 (52-72) years, 33% female]. There was a significant although weak influence of PVS on native T1 (
Conclusion
UNASSIGNED
Despite a weak effect of PVS on native T1, its predictive power was not affected in a large, all-comers cohort.
Identifiants
pubmed: 36865890
doi: 10.3389/fcvm.2023.1091334
pmc: PMC9971619
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1091334Informations de copyright
Copyright © 2023 Treiber, Hausmann, Wolter, Fischer-Rasokat, Kriechbaum, Hamm, Nagel, Puntmann and Rolf.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
JAMA. 1989 Feb 10;261(6):884-8
pubmed: 2913385
JAMA Cardiol. 2020 Nov 01;5(11):1265-1273
pubmed: 32730619
J Am Coll Cardiol. 2002 Jan 16;39(2):210-8
pubmed: 11788209
JACC Cardiovasc Imaging. 2019 Nov;12(11 Pt 2):2357-2368
pubmed: 31542527
JACC Cardiovasc Imaging. 2018 Jan;11(1):38-45
pubmed: 28412435
JACC Cardiovasc Imaging. 2016 Jan;9(1):40-50
pubmed: 26762873
JACC Cardiovasc Imaging. 2021 Jun;14(6):1177-1188
pubmed: 33454266
Circulation. 2010 Jul 13;122(2):138-44
pubmed: 20585010
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
JACC Cardiovasc Imaging. 2016 Jan;9(1):67-81
pubmed: 26762877
Circulation. 2015 Jul 28;132(4):302-61
pubmed: 25547519
J Card Fail. 2018 Sep;24(9):553-560
pubmed: 30098381
Radiology. 2014 Sep;272(3):683-9
pubmed: 24702727
J Cardiovasc Magn Reson. 2020 Sep 7;22(1):63
pubmed: 32892751
J Cardiovasc Magn Reson. 2021 Nov 11;23(1):125
pubmed: 34758850
Eur J Heart Fail. 2019 May;21(5):634-642
pubmed: 30714658
J Cardiovasc Magn Reson. 2016 Nov 30;18(1):89
pubmed: 27899132
JACC Cardiovasc Imaging. 2017 Oct;10(10 Pt A):1180-1193
pubmed: 28982571
J Cardiovasc Magn Reson. 2013 Sep 11;15:78
pubmed: 24025486
J Nucl Med. 2015 Jun;56 Suppl 4:39S-45S
pubmed: 26033902
J Cardiovasc Magn Reson. 2020 Feb 24;22(1):17
pubmed: 32089132
JACC Cardiovasc Imaging. 2018 Jan;11(1):48-59
pubmed: 28624408
JACC Cardiovasc Imaging. 2019 Nov;12(11 Pt 2):2305-2318
pubmed: 31422140
J Cardiovasc Magn Reson. 2015 Jun 11;17:48
pubmed: 26062931
JACC Cardiovasc Imaging. 2021 May;14(5):1038-1052
pubmed: 32828781
J Am Coll Cardiol. 2010 Jul 20;56(4):278-87
pubmed: 20633819
Sci Rep. 2019 Feb 4;9(1):1388
pubmed: 30718606
Curr Heart Fail Rep. 2011 Dec;8(4):233-41
pubmed: 21861070
J Cardiovasc Magn Reson. 2014 Jan 04;16:2
pubmed: 24387626
J Am Coll Cardiol. 2018 Feb 20;71(7):766-778
pubmed: 29447739
Eur J Heart Fail. 2015 Jan;17(1):35-43
pubmed: 25469484
J Cardiovasc Magn Reson. 2017 Feb 27;19(1):21
pubmed: 28238284
JACC Cardiovasc Imaging. 2016 Jan;9(1):14-23
pubmed: 26684970